LivaNova announced it received regulatory approvals and has initiated a targeted commercial launch if its patient-tailored monitoring system for use during cardiopulmonary bypass procedures.
The monitoring system (Essenz), which received clearance from the FDA and other regulatory bodies, provides the perfusionist with decision-making support during the entire cardiopulmonary bypass procedure and is compatible with the company’s heart-lung machine (LivaNova S5), according to a company press release.
“The Essenz Patient Monitor provides advanced and insightful data through one